Subscribe to RSS
DOI: 10.1590/0004-282X-ANP-2022-S124
What’s new in insomnia? Diagnosis and treatment
Quais a novidades em insônia? Diagnóstico e tratamento
ABSTRACT
Although, insomnia is one of the most common diseases that health professionals face in their practice, it receives little attention in medical training. Diagnosis is based on a careful history taking, and physicians must be aware of the diagnostic criteria. Insomnia should not be considered a symptom, but a comorbid condition. Although cognitive behavioral therapy (CBT) has been the mainstay treatment for insomnia for many years, it is usually regarded as a novel therapeutic strategy, both because of scarcity of qualified psychologists and of limited knowledge about insomnia among physicians. GABA receptor acting drugs are being abandoned in the treatment of insomnia because of abuse and dependence potential and accident risk. Two main current therapeutic options with the best scientific evidence are the tricyclic antidepressant, doxepin, and a new melatoninergic receptor agonist, ramelteon. Newer drugs to treat insomnia are in the pipeline. Hypocretine blocking agents will be marketed in the near future.
RESUMO
Embora a insônia seja uma das doenças mais comuns encontrada por profissionais de saúde em sua prática quotidiana, está ainda é negligenciada nos currículos médicos. O diagnóstico baseia-se em anamnese cuidadosa e os médicos devem conhecer os critérios diagnósticos. A insônia não deve ser considerada apenas um sintoma, mas uma comorbidade. Apesar de a terapia cognitivo comportamental (TCC) para insônia ser a principal opção terapêutica há muito anos, esta modalidade terpêutica ainda é considerada uma nova estratégia pela escassez de psicólogos qualificados e pelo desconhecimento médico acerca da insônia. Os fármacos que atuam nos receptores GABA vêm sendo abandonados no tratamento da insônia devido ao potencial de abuso e dependência e pelo risco de acidentes. As duas principais opções terapêutica para insônia com melhor evidência científica são um antigo antidepressivo tricíclico, a doxepina, e um novo agonista do receptor melatoninérgico, a ramelteona. Novas drogas para insônia estão em processo de aprovação regulatória e comercialização. As mais próximas de serem liberadas para o mercado são as drogas bloqueadoras do sistema da hipocretina.
Keywords:
Sleep Initiation and Maintenance Disorders - Cognitive Behavioral Therapy - Hypnotics and SedativesPalavras-chave:
Distúrbios do Início e da Manutenção do Sono - Terapia Cognitivo-Comportamental - Hipnóticos e SedativoAuthors’ contributions:
Both authors performed bibliographic the research. BAC on CBT-I and AP on pharmacological treatment.
Publication History
Received: 21 March 2022
Accepted: 29 April 2022
Article published online:
06 February 2023
© 2022. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
References
- 1 Medicine American Academy of Sleep Medicine. International classification of sleep disorders. 3. Darien (IL): American Academy of Sleep Medicine; 2014
- 2 American Psychiatric Association. Diagnostic and statistical manual of mental disorders. American Psychiatric Association; 2013
- 3 NHI. NIH State-of-the-Science Conference Statement on Manifestations and Management Office of the Director. NIH Consens State Sci Statements 2005; 22 (02) 36
- 4 Bacelar A, Pinto Jr LR. Insônia: do diagnóstico ao tratamento. São Paulo (SP): Associação brasileira de sono; 2019: 174-174
- 5 Edinger JD, Arnedt JT, Bertisch SM, Carney CE, Harrington JJ, Lichstein KL. et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med 2021; 17 (02) 255-262 https://doi.org/10.5664/jcsm.8986
- 6 Sivertsen B, Omvik S, Pallesen S, Bjorvatn B, Havik OE, Kvale G. et al. Cognitive behavioral therapy vs zopiclone for treatment of chronic primary insomnia in older adults: a randomized controlled trial. JAMA 2006; 295 (24) 2851-2858 https://doi.org/10.1001/jama.295.24.2851
- 7 Jacobs GD, Pace-Schott EF, Stickgold R, Otto MW. Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison. Arch Intern Med 2004; 164 (17) 1888-1896 https://doi.org/10.1001/archinte.164.17.1888
- 8 Morin CM, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA 1999; 281 (11) 991-999 https://doi.org/10.1001/jama.281.11.991
- 9 Harvey AG, Tang NKY. Cognitive behaviour therapy for primary insomnia: can we rest yet?. Sleep Med Rev 2003; 7 (03) 237-262 https://doi.org/10.1053/smrv.2002.0266
- 10 Wu JQ, Appleman ER, Salazar RD, Ong JC. Cognitive behavioral therapy for insomnia comorbid with psychiatric and medical conditions: a meta-analysis. JAMA Intern Med 2015; 175 (09) 1461-1472 https://doi.org/10.1001/jamainternmed.2015.3006
- 11 Riedel BW, Lichstein KL. Strategies for evaluating adherence to sleep restriction treatment for insomnia. Behav Res Ther 2001; 39 (02) 201-212 https://doi.org/10.1016/S0005-7967(00)00002-4
- 12 Vincent NK, Hameed H. Relation between adherence and outcome in the group treatment of insomnia. Behav Sleep Med 2003; 1 (03) 125-139 https://doi.org/10.1207/S15402010BSM0103_1
- 13 Ong JC, Manber R, Segal Z, Xia Y, Shapiro S, Wyatt JK. A randomized controlled trial of mindfulness meditation for chronic insomnia. Sleep 2014; 37 (09) 1553-1563 https://doi.org/10.5665/sleep.4010
- 14 Ong JC, Shapiro SL, Manber R. Mindfulness meditation and cognitive behavioral therapy for insomnia: a naturalistic 12-month follow-up. Explore (NY): 2009. 5. 1 30-36 https://doi.org/10.1016/j.explore.2008.10.004
- 15 Ong JC, Smith CE. Using mindfulness for the treatment of insomnia. Curr Sleep Med Rep 2017; 3 (02) 57-65 https://doi.org/10.1007/s40675-017-0068-1
- 16 Gurtman CG, Mcnicol R, Mcgillivray JA. The role of neuroticism in insomnia. Clin Psychol 2014; 18 (03) 116-124 https://doi.org/10.1111/cp.12029
- 17 Bliwise DL, Friedman L, Nekich JC, Yesavage JA. Prediction of outcome in behaviorally based insomnia treatments. J Behav Ther Exp Psychiatry 1995; 26 (01) 17-23 https://doi.org/10.1016/0005-7916(94)00073-u
- 18 Johann AF, Riemann D, Spiegelhalder K. Does perfectionism increase the risk for dropout from cognitive behavioral therapy for insomnia?. J Clin Sleep Med 2018; 14 (03) 487-488 https://doi.org/10.5664/jcsm.7012
- 19 Balon R, Starcevic V, Silberman E, Cosci F, Dubovsky S, Fava GA. et al. The rise and fall and rise of benzodiazepines: a return of the stigmatized and repressed. Braz J Psychiatry 2020; 42 (03) 243-244 https://doi.org/10.1590/1516-4446-2019-0773
- 20 O'Brien CP. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry 2005; 66 (Suppl. 02) 28-33
- 21 Markota M, Rummans TA, Bostwick JM, Lapid MI. Benzodiazepine use in older adults: dangers, management, and alternative therapies. Mayo Clin Proc 2016; 91 (11) P1632-P1639 https://doi.org/10.1016/j.mayocp.2016.07.024
- 22 Gunja N. The clinical and forensic toxicology of Z-drugs. J Med Toxicol 2013; 9 (02) 155-162 https://doi.org/10.1007/s13181-013-0292-0
- 23 Brandt J, Leong C. Benzodiazepines and Z-Drugs: an updated review of major adverse outcomes reported on in epidemiologic research. Drugs R D 2017; 17 (04) 493-507 https://doi.org/10.1007/s40268-017-0207-7
- 24 U.S. Food and Drug Administration. Risk of next‐morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). Saf Accouncement 2013; 6-6
- 25 Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med 2017; 13 (02) 307-349 https://doi.org/10.5664/jcsm.6470
- 26 Riemann D, Baglioni C, Bassetti C, Bjorvatn B, Groselj LD, Ellis JG. et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res 2017; 26 (06) 675-700 https://doi.org/10.1111/jsr.12594
- 27 Mcgechan A, Wellington K. Ramelteon. Ramelteon. CNS Drugs 2005; 19 (12) 1057-1065 https://doi.org/10.2165/00023210-200519120-00007
- 28 Atkin T, Comai S, Gobbi G. Drugs for insomnia beyond benzodiazepines: pharmacology, clinical applications, and discovery. Pharmacol Rev 2018; 70 (02) 197-245 https://doi.org/10.1124/pr.117.014381
- 29 Smaglik P. New perspectives. Nature 2003; 425 6958 643 https://doi.org/10.1038/nj6958-643a
- 30 Abad VC, Guilleminault C. Insomnia in elderly patients: recommendations for pharmacological management. Drugs Aging 2018; 35 (09) 791-817 https://doi.org/10.1007/s40266-018-0569-8
- 31 Roch C, Bergamini G, Steiner MA, Clozel M. Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia. Psychopharmacology (Berl) 2021; 238 (10) 2693-2708 https://doi.org/10.1007/s00213-021-05954-0
- 32 Recourt K, de Boer P, Zuiker R, Luthringer R, Kent J, van der Ark P. et al. The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder. Transl Psychiatry 2019; 9 (01) 216 https://doi.org/10.1038/s41398-019-0553-z
- 33 Zisapel N. Current phase II investigational therapies for insomnia. Expert Opin Investig Drugs 2015; 24 (03) 401-411 https://doi.org/10.1517/13543784.2015.987340
- 34 Kesner AJ, Lovinger DM. Cannabinoids, endocannabinoids and sleep. 2020. 13. 125 https://doi.org/10.3389/fnmol.2020.00125